Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9251598 | 1.00 | CHRNB2 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL459030 | 0.87 | — | — | |
| SCHEMBL971678 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL10808909 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL11798752 | 0.85 | CHRNB2 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10337082 | 0.85 | CHRNB2 (0.36) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL9249984 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19263973 | 0.82 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1571722 | 0.82 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL9249995 | 0.82 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103880597-A | Co-production method and device of cyclohexanol and ethanol | CHINA PETROLEUM & CHEMICAL | 2014-06-25 | — | — | CN | claimed |
| JP-5163192-A | — | — | None | — | — | JP | disclosed |
| JP-5103690-A | — | — | None | — | — | JP | disclosed |
| US-8946468-B2 | Process for producing ester compound having an internal unsaturated bond or cyclic olefin | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| CN-103880597-A | Co-production method and device of cyclohexanol and ethanol | CHINA PETROLEUM & CHEMICAL | 2014-06-25 | — | — | CN | disclosed |
| WO-2014079850-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-30 | — | — | WO | disclosed |
| US-20120316360-A1 | PROCESS FOR PRODUCING ESTER COMPOUND HAVING a,ß-UNSATURATED BOND | OSAKA UNIVERSITY (JP) | 2012-12-13 | — | — | US | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
| JP-H05163192-A | OPTICAL RESOLUTION OF 2-CYCLOHEXENYL ACETIC ACID | DAICEL CHEM IND LTD | 1993-06-29 | — | — | JP | disclosed |
| JP-H05103690-A | PRODUCTION OF OPTICALLY ACTIVE 2-CYCLOHEXENYLACETIC ACID AND ITS ESTER | DAICEL CHEM IND LTD | 1993-04-27 | — | — | JP | disclosed |
| EP-0415776-A2 | Indolobenzoquinoline derivatives, their preparation and their use as anti-arrhythmic drugs | Sankyo Company Limited (JP) | 1991-03-06 | — | — | EP | disclosed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0059158-B1 | AZA PROSTACYCLINS, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-08-03 | — | — | EP | disclosed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
| US-4567195-A | Azaprostacyclins, their preparation and pharmaceutical use | SCHERING, AKTIENGESELLSCHAFT (DE) | 1986-01-28 | — | — | US | disclosed |
| US-4446147-A | Azaprostacyclins, their preparation and pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-05-01 | — | — | US | disclosed |
| EP-0059158-A2 | Aza prostacyclins, their preparation and therapeutic applications | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316360-A1 | PROCESS FOR PRODUCING ESTER COMPOUND HAVING a,ß-UNSATURATED BOND | COASY, OXER1, ACSL1 | CHRNB2 2440/4885CHRNA3 3414/4885CHRNA4 2678/4885 |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | USP24, USP36, USP39 | CHRNB2 3692/4885CHRNA3 3772/4885CHRNA4 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.